WallStreetZenWallStreetZen

NASDAQ: DMRA
Damora Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for DMRA

Based on 4 analysts offering 12 month price targets for Damora Therapeutics Inc

Min Forecast
$40.00+54.44%
Avg Forecast
$44.25+70.85%
Max Forecast
$46.00+77.61%

Should I buy or sell DMRA stock?

Based on 4 analysts offering ratings for Damora Therapeutics Inc.

Strong Buy
Strong Buy
2 analysts 50%
Buy
2 analysts 50%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although DMRA's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates DMRA as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their DMRA stock forecasts and price targets.

DMRA stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-03-25
lockedlocked$00.00+00.00%2026-02-17
lockedlocked$00.00+00.00%2026-02-17Find Out Why
lockedlocked$00.00+00.00%2026-01-07

1 of 1

Forecast return on equity

Is DMRA forecast to generate an efficient return?

Company
N/A
Industry
69.63%
Market
179.33%

Forecast return on assets

Is DMRA forecast to generate an efficient return on assets?

Company
N/A
Industry
31.99%

DMRA earnings per share forecast

What is DMRA's earnings per share in the next 2 years based on estimates from 5 analysts?

Avg 1 year Forecast
-$1.09-127.42%
Avg 2 year Forecast
-$1.51-138.02%

DMRA revenue forecast

What is DMRA's revenue in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$0.0

DMRA vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
DMRA$25.90$44.25+70.85%Strong Buy
OCS$26.59$42.00+57.95%Strong Buy
AMLX$13.90$23.83+71.46%Strong Buy
TRVI$11.93$20.56+72.31%Strong Buy
NRIX$15.50$31.10+100.65%Strong Buy
View Top Biotech Stocks

Damora Therapeutics Stock Forecast FAQ

Is Damora Therapeutics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 4 Wall Street analysts covering (NASDAQ: DMRA) stock is to Strong Buy DMRA stock.

Out of 4 analysts, 2 (50%) are recommending DMRA as a Strong Buy, 2 (50%) are recommending DMRA as a Buy, 0 (0%) are recommending DMRA as a Hold, 0 (0%) are recommending DMRA as a Sell, and 0 (0%) are recommending DMRA as a Strong Sell.

If you're new to stock investing, here's how to buy Damora Therapeutics stock.

What is DMRA's earnings growth forecast for 2026-2027?

(NASDAQ: DMRA) Damora Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.91%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 36.24%.

Damora Therapeutics's earnings in 2026 is -$209,839,000.On average, 5 Wall Street analysts forecast DMRA's earnings for 2026 to be -$65,814,926, with the lowest DMRA earnings forecast at -$74,462,406, and the highest DMRA earnings forecast at -$60,152,454.

In 2027, DMRA is forecast to generate -$91,238,760 in earnings, with the lowest earnings forecast at -$125,876,925 and the highest earnings forecast at -$58,252,903.

What is DMRA's revenue growth forecast for 2026-2029?

(NASDAQ: DMRA) Damora Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.45%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.54%.

Damora Therapeutics's revenue in 2026 is $0.On average, 4 Wall Street analysts forecast DMRA's revenue for 2026 to be $0, with the lowest DMRA revenue forecast at $0, and the highest DMRA revenue forecast at $0. On average, 4 Wall Street analysts forecast DMRA's revenue for 2027 to be $0, with the lowest DMRA revenue forecast at $0, and the highest DMRA revenue forecast at $0.

In 2029, DMRA is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is DMRA's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: DMRA) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 31.99%.

What is DMRA's Price Target?

According to 4 Wall Street analysts that have issued a 1 year DMRA price target, the average DMRA price target is $44.25, with the highest DMRA stock price forecast at $46.00 and the lowest DMRA stock price forecast at $40.00.

On average, Wall Street analysts predict that Damora Therapeutics's share price could reach $44.25 by Mar 25, 2027. The average Damora Therapeutics stock price prediction forecasts a potential upside of 70.85% from the current DMRA share price of $25.90.

What is DMRA's Earnings Per Share (EPS) forecast for 2026-2027?

(NASDAQ: DMRA) Damora Therapeutics's current Earnings Per Share (EPS) is $3.98. On average, analysts forecast that DMRA's EPS will be -$1.09 for 2026, with the lowest EPS forecast at -$1.23, and the highest EPS forecast at -$1.00. In 2027, DMRA's EPS is forecast to hit -$1.51 (min: -$2.09, max: -$0.97).

What is DMRA's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: DMRA) forecast ROE is N/A, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.